ALPN News and Press, Alpine Immune Sciences Inc. From 10/24/22

- Company’s primary focus will be the pursuit of expedited development plans for ALPN-303 in multiple autoimmune and inflammatory indications - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innova...

FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James “Jamie...

Alpine Immune Sciences ( NASDAQ: ALPN ) has priced its underwritten public offering of 13.61M shares of its common stock at a public offering price of $7.35/share for expected gross proceeds to be ~$100.0M. Underwriters are granted a 30 days to purchase up to an additional...

Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the pricing of its underwritten public offering of 13,606,000 shares of its common stock p...

Alpine Immune Sciences ( NASDAQ: ALPN ) stock dropped 13% after the bell on Tuesday after the firm announced an underwritten public offering of $100M of shares and pre-funded warrants to buy stock. Underwriters will be granted an option for 30 days to buy up to an addition...

Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that it has commenced an underwritten public offering of $100.0 million of shares of its c...

- ALPN-303 well-tolerated in a Phase 1 healthy volunteer study with on-target effects on key biomarkers, supporting a highly competitive, potentially best in class profile - - Davoceticept (ALPN-202) demonstrates encouraging outcomes, especially in renal cell carcinoma, as mon...

- Clinical data update from a first-in-human phase 1 study of ALPN-303 in healthy adults and plans for multiple patient-based studies beginning in 2023 - - First look at data from NEON-2 study of davoceticept in combination with pembrolizumab in advanced malignancies - ...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced that, in connection with the previously announced appointment of Andrew S. Sandler, M.D. as C...

Alpine Immune Sciences press release ( NASDAQ: ALPN ): Q2 GAAP EPS of -$0.60 misses by $0.21 . Revenue of $5.29M (-26.4% Y/Y) misses by $4.75M . For further details see: Alpine Immune Sciences GAAP EPS of -$0.60 misses by $0.21, revenue of $5.29M misses b...